Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Comprehensive Look At Rare Leukemia Finds Relatively Few Genetic Changes Launch Disease
The most comprehensive analysis yet of the genome of childhood acute myeloid leukemia (AML) found only a few mistakes in the genetic blueprint, suggesting the cancer arises from just a handful of missteps, according to new findings from St. Jude Children"s Research Hospital. The research appears in the July 27 online edition of the Proceedings of the National Academy of Sciences.

ARIAD Announces Preliminary Results From Ongoing Clinical Trial Of Its Investigational, Bcr-Abl Inhibitor In Drug-Resistant Chronic Myeloid Leukemia
ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) announced preliminary clinical data from an ongoing Phase 1 clinical trial of its investigational, multi-targeted kinase inhibitor, AP24534, in patients with advanced hematological cancers. The study results provide initial clinical evidence of hematologic, cytogenetic and molecular anti-cancer activity of AP24534 in heavily pretreated patients with resistant and refractory chronic myeloid leukemia (CML), including those with the T315I mutant variant of the target protein, Bcr-Abl. An abstract describing these data is being submitted for presentation at a major hematology meeting to be held later this year.
News of the day
Halozyme Begins Phase 2 Clinical Trial Of Insulin-PH20 In Type 2 Diabetic Patients
Halozyme Therapeutics, Inc. (Nasdaq:HALO) today announced the commencement of patient dosing in a Phase 2 clinical study of Insulin-PH20 in patients with Type 2 Diabetes Mellitus. This randomized cross-over design study is designed to compare the postprandial glycemic excursions following a standardized test meal after treatment with either insulin lispro+PH20 or regular insulin+PH20 relative to treatment with lispro (Humalog) alone.
Endocrinology

Minister Brady Announces Publication Of 2008 Annual Report Of The Alcohol Marketing Communications Monitoring Body, Ireland

Ms Aine Brady T.D. Minister for Older People and Health Promotion, announced the publication of the 2008 Annual Report from the Alcohol Marketing Communications Monitoring Body (AMCMB). The AMCMB was established to monitor the level of adherence by advertisers and media owners to the Codes of Practice on Alcohol Marketing, Communications and Sponsorship. The AMCMB has concluded that there continues to be overall compliance with the Codes. The Codes of Practice, which have been agreed between the Department of Health and Children and the Irish alcohol industry and the Irish advertising industry, are in place to limit the exposure of children and young people to alcohol advertising in Ireland. These Codes are intended to be complementary to existing statutory obligations and other voluntary codes that exist such as the codes of the Broadcasting Commission of Ireland and the Advertising Standards Authority for Ireland. "The Codes on Advertising and Sponsorship, which are in place in Ireland, are among the strongest voluntary Codes in place in the European Union. However, there is no reason to be complacent and we will continue to monitor adherence to the Codes and to identify what further measures that might be necessary to reduce exposure of children and young people to alcohol advertising." The Minister said Read the Report Department of Health and Children, Ireland


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009